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Editorial on the Research Topic
Biomarkers in Leishmaniasis
INTRODUCTION
Leishmaniasis is one of the most deadly, yet neglected, of all tropical diseases (Alvar et al.,
2012). The eco-epidemiological characteristics of leishmaniasis render it a complex problem.
There are over 20 species of leishmaniasis pathogens transmitted by different species of sand fly
(Phlebotomus spp.). Transmission may be anthroponotic or zoonotic, the latter entailing different
animal reservoirs. Depending on the species of Leishmania and the immune response to it, the
diseasemay present as cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral
leishmaniasis (VL), or post-kala azar dermal leishmaniasis (PKDL) (Burza et al., 2018).
The complexity of leishmaniasis means different strategies are needed if it is to be controlled and
eliminated (Matlashewski et al., 2014; Rijal et al., 2019). For example:
- Diagnostic methods need to be faster and simpler, but sensitive and robust, and allow early
diagnoses to be made. Follow-up methods are also needed that confirm patient responses and
help predict the risk of relapse.
- Efficient therapies for the different forms of the disease need to be developed, both for the
immunocompetent and the immunodepressed.
- Methods of controlling animal reservoirs—especially domestic animal reservoirs—need to be
developed; alongside better vectorial control these should reduce the transmission of the parasite.
- The capacity of asymptomatic carriers to pass on the disease needs to be examined—an important
challenge for control programs.
- A vaccine against the different forms of leishmaniasis needs to be developed; this might be the
best means of control and protection, but work is needed on how to immunize most effectively
for the lowest cost.
Biomarkers have a central role to play in the above challenges by providing information on patient
immune status, the response to treatment, exposure to vectors, the role of animal reservoirs,
and the epidemiology of infection, etc. New biomarkers need to be found that will allow the
development of tools for assessing the effectiveness of treatments, that can confirm when a cure
has been achieved, to identify asymptomatic persons and rates of transmission in endemic areas, to
develop rapid, non-invasive tests, and for checking the immune response to experimental vaccines
(Ibarra-Meneses et al., submitted).
This Research Topic, entitled “Biomarkers in Leishmaniasis”, is a collection of 19 articles, some
of which examine the latest advances in biomarkers of the different types of leishmaniasis, while
others report original research into biomarker identification and characterization.
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DIAGNOSTIC AND DISEASE PROGRESS
BIOMARKERS
Several articles in the cited collection examine the identification
of new biomarkers useful for understanding the pathogenesis
of leishmaniasis, and for improving its diagnosis. The clinical
complexity and epidemiology of leishmaniasis is a challenge
in the identification of biomarkers able to track the progress
of the disease. This is made clear by different review articles
that focus on its different clinical forms. The work of Brodskyn
and Kamhawi on biomarkers of zoonotic VL in Latin America,
focuses on humans and dogs, and addresses the need to
examine a combination of inflammatory mediators for the
development of a tool that distinguishes between the different
stages of the disease. They also discuss the use of serum
antibodies against the highly immunogenic salivary proteins of
Lutzomyia as biomarkers of exposure to the vector in humans
and dogs.
In their review, Bahrami et al. highlight the scarcity of
specific markers for CL. Apart from abnormalities in the
delayed hypersensitivity test, in T cell subpopulations, cytokine
levels and enzyme (e.g., adenosine deamidase and L-argininase)
concentrations, these authors suggest the need to develop
analyses based on comparing the transcriptome of the lesion
with that of healthy skin (Christensen et al., 2016; Masoudzadeh
et al., 2017). The identification of biomarkers able to predict
the result of infection by different species of Leishmania is
also a major challenge in CL (Patino and Ramírez, 2017).
For example, the physiopathology of PKDL (which follows
VL in some treated patients) is different to that of both VL
and CL (Kip et al., 2015), and patients show responses to
treatment that are difficult to assess (the lesions can take a
long time to heal, thus responses may take time to appear).
In their review, Zijlstra indicate that current biomarkers for
PKDL lesions are unsatisfactory. Certainly, clinical assessment
is subjective and not very precise, and while the parasite load
can be determined by qPCR, serological tests such as DAT, rK39
ELISA, and rK39 RDT lack specificity since antibodies may
hang over from previous bouts of VL. Moreover, the systemic
and skin immune responses are different. Zijlstra also questions
whether biomarkers in the blood (such as cytokines or cell
populations) properly reflect skin-level changes, and declares
that new avenues need to be explored. These might include 3D
optical scanning and the undertaking of longitudinal studies
that can provide a description of PKDL before, during and
after cure.
Dogs play a major role in the transmission of the parasite
to humans (Moreno and Alvar, 2002). The present collection
therefore also includes an article by Maia and Campino which is
exclusively devoted to canine leishmaniasis. This review discusses
the latest advances in the identification of biomarkers associated
with infection by L. infantum in dogs. The early detection and
treatment of infected animals is a basic requirement in the
control of human VL (Alvar et al., 2004). Canine leishmaniasis
has a wide spectrum of manifestations, the result of complex
host-parasite interactions (Reis et al., 2010), and these authors
conclude that no single biomarker is able to confirm a diagnosis,
reflect the effectiveness of treatment, or indicate the infectivity of
affected dogs.
In their contribution, Ontoria et al. report the expression of
different genes in the spleens of infected and control Balb/c mice,
the final aim of their research being to better understand the
immunological mechanisms that lead to protection or disease
progression, and the identification of associated biomarkers.
d’El-Rei Hermida et al. review the histological changes that occur
in the spleen in severe VL, and record the events that eventually
lead to its destruction. Garde et al. discuss markers of disease
progression, reporting on the antigenicity of Leishmania antigens
and the role of the eukaryotic initiation factors F2, F2B, LieIF2,
and LieIF2B. These proteins, to which specific antibodies were
detected in the serum of patients with VL, and in dogs with
canine leishmaniasis, induce a humoral response in a murine
model, along with the production of IL-10. IL-10 favors the
progression of the disease and therefore could act as an indicator
of the same.
Piel et al. propose experimentally infecting mice with cosmid-
transfected parasites as a means of searching for new genetic
markers. This might allow the identification of genetic loci
associated, for example, with resistance to medications, or
that might act as new treatment targets. Any factors thus
identified, however, would have to be validated in specific
field studies.
BIOMARKERS OF CURE
Some of the articles included in this Research Topic focus on the
identification of new biomarkers associated with the response to
treatment, and that provide confirmation of cure. A biomarker
that indicates a cure to have been achieved could be used to
reduce treatment times and prevent relapses, help adjust doses,
and be of use in research into new treatments or combinations
of current medications (Alves et al., 2018). Marlais et al. report
results obtained in a clinical trial involving patients with VL
in which they measured Leishmania-specific IgG1 in the serum
before and after treatment. Using the VL Sero K-SeT rapid
diagnostic test and ELISA, they show that high post-treatment
concentrations of these antibodies are associated with relapse,
while low (or no) concentrations are associated with cure. They
also report the above rapid diagnostic test may be of help in the
diagnosis of PKDL.
In the search for biomarkers that indicate the cure of CL,
Montoya et al. report the use of a hamster model to analyse skin
lesions for the production of the growth factors EGF, TGFbeta1,
PDGF, and FGF. They indicate an increase in TGFbeta1 to
be associated with active disease, while high EGF levels are
associated with the cure of the lesion. They conclude that the
EGF/TFGbta1 ratio might provide an excellent biomarker of
the establishment of an infection or an adequate response to
treatment. Kip et al. investigate the role of neopterin, a marker
of macrophage activation, and its association with the response
to treatment for VL. These authors examine the plasma neopterin
concentration before and after treatment and discuss its potential
for identifying patients at risk of suffering an early relapse.
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Botana et al. compare serological, parasitological and
cellular response biomarkers in patients with different forms
of leishmaniasis caused by L. infantum. Their work, which
was performed with patients with active disease plus others
who had been cured, shows significant differences in the
results of pre- and post-treatment parasitological tests (they
became negative), and in cellular immunity tests (they became
positive). However, no changes to the outcome of serological
tests were seen. These authors conclude peripheral blood
mononuclear cell (PBMC) proliferation following stimulation
with Leishmania antigens, and the secretion of IFN-gamma,
to be good markers of cure of VL. However, for CL,
MCL, and localized leishmanial lymphadenopathy (LLL), these




Many of the articles in this Research Topic insist on the
importance of identifying biomarkers of asymptomatic infection.
This is necessary if we are to know the true prevalence of
Leishmania infection in any determined area, and for designing
strategies to control the disease (Alvar et al., submitted). The
search for such biomarkers is limited, however, by the deficient
definition of an asymptomatic patient as “someone in an
endemic area who has an immune response (antibody- or cell-
based) against Leishmania but who remains healthy.” This partly
explains why, to date, there is no reference method for detecting
asymptomatic infection.
This collection of articles contains two original research
papers that focus on asymptomatic infection. Best et al. report
that in asymptomatic persons who had traveled to areas where
American tegumentary leishmaniasis (ATL) is endemic, the
expression of IFN-gamma following the stimulation of their
PBMC with Leishmania antigens is directly related to the length
of time spent in the area. This can provide information on how
long the asymptomatic condition can last.
In very different work, Coutinho-Abreu and Valenzuela
provide a comparative phylogenetic analysis of the proteins in
sand fly saliva, and report differences in the amino acid sequence
of those of New World and Old World flies, and indeed proteins




The search for biomarkers that correlate with the degree of
protection achieved are vital in the development of Leishmania
vaccines (Moreno, 2019). Several contributions to this Research
Topic focus on the immune response to the parasite, and on
parasite antigens that might be candidates for use in vaccine
production. Egui et al. examine the functional and phenotypic
profiles of Leishmania-specific CD4+ and CD8+ cells from
patients cured of CL caused by L. panamensis, as well as those
of healthy, asymptomatic patients, and report that protection
against the disease is associated with an increased cytotoxic T cell
response—something that could be very useful when monitoring
patients. Boussoffara et al. come to a similar conclusion in their
article on CL caused by L. major, and report that high levels
of granzyme B are associated with better protection against the
development of CL. It could therefore be a useful biomarker for
assessing the effectiveness of vaccines. As mentioned by Ontoria
et al., combining transcriptomic, proteomic, and metabolomic
analyses may be of great interest when studying the factors
involved in the cellular response, and for identifying biomarkers
of infection. The review by Tavares-Veras et al. goes deeper
into this question and discusses large scale studies that have
identified and assessed biomarkers in infected macrophages. The
parasite alters the protein profile of these cells, rendering them
suitable for proteomic studies aimed at identifying newmolecular
biomarkers that might reveal the destiny of the host cell and
pathogen (Jean Beltran et al., 2017).
BIOMARKERS OF COINFECTION WITH HIV
AND LEISHMANIA
Since many of the biomarkers identified are related to the host
immune response, others need to be sought for use in situations
in which no immune response occurs. Immunodepression
increases the risk of developing leishmaniasis, alters the clinical
spectrum of the disease, and increases the risk of therapeutic
failure and relapse (van Griensven et al., 2014). Biomarkers for
monitoring patients coinfected with Leishmania, and HIV, and
who suffer from some other form of immunodepression, are
therefore needed (Akuffo et al., 2018). The present collection
contains two articles on the search for biomarkers for the former.
In their work, aimed at identifying early markers of susceptibility
or resistance to VL in patients with HIV, Adriansen et al.
examine the serum levels of macrophage activators (sCD40L and
neopterin) in such patients, and confirm that they are reduced in
those with active VL, and increased in those with asymptomatic
Leishmania infection. These markers could be useful when
trying to predict the progress of disease in such patients. In
contrast, van Griesvan et al. focus on the identification of
biomarkers of therapeutic failure for VL and disease relapse in
coinfected persons. This research paper shows that coinfected
patients with high levels of Leishmania antigens in their urine
at the moment of diagnosis of VL are at greater risk of
therapeutic failure. In addition, those with high levels at the
end of treatment are more likely suffer a relapse within 12
months. These results highlight the importance of antigenuria in
monitoring the response to treatment and the risk of relapse in
immunodepressed patients.
CONCLUSIONS
The present collection of articles underscores the main problems
faced in identifying biomarkers of leishmaniasis, and show that
much work is needed to validate those already found. It is
important that the knowledge we have be used in innovative ways
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resulting in novel clinical applications and rapid, sensitive and
simple diagnostic tests.
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